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Abstract
EphB receptors and their ephrinB ligands play a key
role in the formation of a regular vascular system. Re-
cent studies have also shown the involvement of
Eph/ephrin interactions in malignant tumor progres-
sion and angiogenesis. We have generated soluble
monomeric EphB4 (sEphB4)–expressing A375 mela-
noma cells to study the effect of dominant negatively
acting sEphB4 on tumor growth and angiogenesis.
Soluble EphB4-expressing A375 tumors grown sub-
cutaneously in nude mice show dramatically reduced
tumor growth compared to control tumors. The pro-
liferative capacity of sEphB4-expressing cells in
monolayer culture is not altered. Yet, sEphB4-express-
ing A375 cells cannot establish proper cell–cell
contacts in three-dimensional spheroids. However,
sEphB4 transfectants have reduced proliferation and
apoptosis rates when grown in three-dimensional
culture in vitro or in subcutaneous tumors in vivo.
Analysis of the vascular phenotype of the tumors
revealed a reduction of intratumoral microvessel
density in sEphB4-expressing tumors. Corresponding
to these mouse experiments, a matched pair analysis
of EphB4 and ephrinB2 expression in human colon
carcinomas revealed significantly upregulated levels
of EphB4 expression compared to adjacent normal
tissue. Taken together, the data identify dual effects of
sEphB4 on the tumor and the vascular compartment
that collectively inhibit tumor growth.
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Introduction
Eph receptors and their corresponding ephrin ligands com-
prise the largest family of receptor tyrosine kinases [1,2].
In contrast to classical transmembrane receptor and cor-
responding secreted ligand signaling systems, both Eph
receptors and ephrin ligands are membrane-bound mole-
cules. EphrinA ligands are glycosyl phosphatidyl inositol
(GPI)-anchored molecules, whereas ephrinB ligands are
transmembrane molecules. EphrinB molecules contain cy-
toplasmic tyrosine and serine phosphorylation sites and
have PDZ domain protein engagement capacity, enabling
them to act as signaling molecules themselves [2,3]. EphB/
ephrinB receptor ligand interactions therefore mediate bidirec-
tional signaling events on direct cell–cell contact [2,4,5]. These
provide positive (attractive) and negative (repulsive) positional
guidance cues to EphB/ephrinB–expressing cells and regulate
adhesive, migratory, and invasive cellular functions [1,2].
Originally identified as neuronal pathfinding molecules [6],
genetic loss-of-function experiments have revealed members
of the EphB/ephrinB family as critical mediators of vascular
assembly and organization, particularly as they relate to the
acquisition of arteriovenous identity [7–9]. Arterial endothelial
cells selectively express ephrinB2 and venous endothelial
cells preferentially express EphB4 [10,11], and mice with
deletions of these molecules exhibit an embryonic lethal phe-
notype as a consequence of a grossly perturbed vascular
architecture [7–9]. Elegant genetic loss-of-function experi-
ments have shown that bidirectional EphB/ephrinB signaling
in the vascular system is critically required for proper develop-
mental arteriovenous differentiation [12]. Corresponding func-
tional experiments support an arteriovenous push-and-pull
model of vascular morphogenesis and vessel assembly with
proangiogenic and arteriolizing functions of ephrinB2 and a
repulsive function of EphB4 signaling [13].
Recently, Eph/ephrin interactions have also been shown
to transduce positional guidance cues in epithelial cells, most
notably during colonic epithelial cell differentiation [14]. The
expression of different Eph receptors and ephrin ligands has
been reported to occur in a number of carcinomas including
colon and lung tumors, suggesting a possible involvement of
Eph/ephrin signaling during tumor progression [15–17]. Over-
expression of EphA2 induces malignant transformation and
confers tumorigenic potential on nontransformed mammary
epithelial cells [18]. EphA2 as well as its ligand ephrinA1 were
found to be expressed by both endothelial cells and various
human tumor cells, thereby establishing a microenvironment
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that stimulates tumor neoangiogenesis by activating EphA2
receptors expressed on angiogenic endothelial cells [17].
Blocking of EphA class receptor activation by competitively
acting soluble EphA receptors has been shown to inhibit
tumor angiogenesis in two different tumor models [19]. Inter-
estingly, stimulation of EphA2 phosphorylation by an EphA2-
specific antibody inhibits the malignant behavior of breast
tumor cells, indicating that EphA2 signaling may induce
different phenotypes in endothelial and tumor cells [20].
In contrast to the EphA/ephrinA receptor ligand system
[21], much less is known about the functions of B class
Eph/ephrin molecules during tumorigenesis. Several studies
have demonstrated the expression of B class Eph/ephrin
molecules in different tumors and suggested a functional
relationship between Eph/ephrin expression and tumor pro-
gression [16,22–28]. Based on these findings and the
established role of bidirectional EphB4/ephrinB2 signaling
during angiogenesis, we hypothesized that soluble Eph
receptors may interfere with tumor growth and angiogenesis.
Consequently, we generated soluble EphB4-expressing
A375 melanoma cells and studied their tumorigenic and
angiogenic properties. The experiments revealed that solu-
ble EphB4 receptor interferes with tumor growth directly, by
affecting tumor cell functions, and indirectly, by inhibiting
endothelial cell functions.
Materials and Methods
Cells, Antibodies, Growth Factors, and Reagents
Human umbilical vein endothelial cells (HUVECs) were
freshly isolated from human umbilical veins of newborn
babies by collagenase digestion. SVEC4-10 (CRL-2181)
endothelial cells and A375 melanoma cells (CRL-1619) were
from the ATCC (Manassas, VA). Fetal calf serum (FCS) was
obtained from Biochrom (Berlin, Germany). Endothelial cell
growth medium (ECGM) and endothelial cell growth supple-
ment (HUVEC culture) were purchased from Promocell
(Heidelberg, Germany). Recombinant mouse EphB4-Fc,
anti– murine EphB4 antibody, and human recombinant
vascular endothelial growth factor (VEGF) were obtained
from R&D Systems (Wiesbaden, Germany). Rat anti –
mouse CD31 antibody MEC 13.3 was purchased from
Pharmingen (Hamburg, Germany). Rat anti–mouse CD34
antibody MEC 14.7 was obtained from HyCult (Uden, The
Netherlands). The proliferation marker rabbit anti–human
phospho-H3 was from Upstate Biotechnology (Biomol, Ham-
burg, Germany). Soluble mouse monomeric EphB4
(sEphB4) was produced by extracting and reverse-transcrib-
ing RNA from RENCA tumors [29] using primers specific for
the extracellular domain of EphB4 (1.620-bp fragment of bp
1–1620 corresponding to aa 1–540). The sequence was
amplified by reverse transcription polymerase chain reaction
(RT-PCR) and verified by sequencing. The fragment was
subcloned in frame with 6  His–Myc tags into KS vector
(NcoI digest). The extracellular domain of EphB4 with
6  His–Myc tags was subcloned into pVL1392 vector
(Biosciences, Heidelberg, Germany). Sf9 insect cells were
infected with Baculogold DNA (pACGP67A; Pharmingen)
and pVL1392mEphB4-Myc. The protein produced in the
Sf9 supernatant was purified by coupling with agarose beads
(Qiagen, Hilden, Germany) overnight at 4jC. Samples were
passed through a column, washed, and eluted by adding 100
mM imidazole. Different fractions were analyzed by silver
staining, dialyzed against phosphate-buffered saline (PBS),
and stored at 20jC.
Transfection and Selection of A375 Melanoma Cells
Soluble monomeric EphB4-transfected A375 melanoma
cells were generated by transfecting the cells with the 1.620
bp sEphB4 cDNA subcloned into pCDNA3 vector (Invitro-
gen, Karlsruhe, Germany) using the mammalian transfection
kit (Stratagene, Amsterdam, The Netherlands) according to
the manufacturer’s instructions. Transfected cells were prop-
agated by cell culture in Dulbecco’s modified Eagle’s me-
dium (DMEM) selection medium containing 10% FCS and
1 mg/ml G418.
RT-PCR
Total cellular RNA was isolated from A375 by using the
RNAeasy kit (Qiagen) according to the manufacturer’s
instructions. cDNA were synthesized using 1 mg of RNA
preheated to 65jC for 10 minutes. The cDNA synthesis
was done with RT (Invitrogen), 1  first strand buffer (Invi-
trogen), 25 mM dNTP (PeqLab, Erlangen, Germany), 0.1 M
DTT (Invitrogen), and random primers (Biolaboratories,
Beverly, MA) for 1 hour at 37jC. For each reaction, a control
without RT was processed in parallel. For PCR reactions, 1 ml
of cDNA was mixed with specific primers (10 pmol each),
2.5 U of Taq DNA polymerase (Invitrogen), 5 ml of
10  reaction buffer, and 10 nmol of dNTPmix (PeqLab) in
a final volume of 50 ml. PCR reactions were carried out in a
Perkin-Elmer thermocycler (Perkin-Elmer, Norwalk, CT) as
follows: 2 minutes at 94jC, 30 seconds at 94jC, 60 seconds
at 60jC or 55jC, followed by 60 seconds at 72jC for 35
cycles. The last cycle was terminated with 7minutes at 72jC.
The following primers were used: EphB1s: CTG AAC ACC
ATC CGC ACC TAC C; EphB1as: CCC CGT AGT AGA GTT
TGA T; EphB2s: CTG TCC CGC AGC GGC TTC; EphB2as:
GGC CCC TTC AGA AGT GGT CC; EpB3s: GAA TCC CAT
CCG CAC ATA CCA G; and EphB3as: GCA CCC ACA GGC
ACC ATC CAC T.
Northern Blot Analysis
Total cellular RNA was isolated from cultured cells and
matched pair biopsies of human colon tumors and adjacent
tissue were taken at surgery. RNA was separated in formal-
dehyde-containing agarose gels, transferred to nylon mem-
branes, and hybridized to 32P-DNA–labeled EphB4 and
ephrinB2 probes (950-bp human EphB4 probe from the
extracellular domain; 1.002-bp full-length human ephrinB2)
as described previously [30].
Western Blot Analysis
Mock and transfected A375 cells were cultured for 48
hours, and conditioned media were collected and incubated
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overnight with 1 mg of ephrinB2-Fc precoupled with protein
G agarose. Precipitates were washed, denatured, and run
on a 10% sodium dodecyl sulfate polyacrylamide gel
electrophoresis (SDS-PAGE) gel. Then probes were blotted
onto a PVDF membrane (Amersham Pharmacia), blocked
with a 3% bovine serum albumin (BSA) solution, and incu-
bated with goat anti–murine EphB4 (R&D Systems). After
adding rabbit-anti-goat HRP (DAKO, Glostrup, Denmark),
the probes were visualized by chemiluminescence (expected
size, 75 kDa).
Proliferation Assay
Wild-type and sEphB4-transfected A375 cells were seed-
ed at a density of 103 cells per 75 cm2 in DMEM containing
10% FCS. The cell number was determined by counting the
cells in five randomly selected microscopic fields ( 100
magnification), 6 hours (day 0) and every 24 hours thereafter
for 7 days.
Soft Agar Colony Assay
Cells (5  103) per well in top agarose (0.5 ml of 0.4%
agarose in DMEM/5% FCS) were layered onto bottom
agarose (0.5 ml of 0.4% agarose in DMEM, 5% FCS) in
24-well plates. Cells were incubated for 14 days at 37jC, and
the colonies were counted.
Cell Cycle Analysis by Fluorescence-Activated Cell Sorter
(FACS)
Colonies grown in soft agar for 13 days were picked and
dissociated with 0.02% EDTA in PBS to obtain a single-cell
suspension. Cells were counted in a Neubauer chamber and
fixed in methanol. The cells were pelleted, rehydrated in PBS
for 30 minutes, pelleted again, and stained in a solution of
25 mg of propidium iodide and 100 mg of RNase A per milliliter
for 30 minutes. Flow cytometric analysis was performed on a
Becton Dickinson (Heidelberg, Germany) FACS Calibur, and
data from 10,000 cells per sample were analyzed with the
CellQuest Cell Cycle Analysis software (Becton Dickinson).
Generation of Three-Dimensional Spheroids
A375 melanoma and HUVEC spheroids of defined cell
number were generated as described previously [31]. Cells
were suspended in culture medium containing 0.25% (wt/vol)
methylcellulose and seeded in nonadherent round-bottom
96-well plates (Greiner, Frickenhausen, Germany). Under
these conditions, all suspended cells contribute to the for-
mation of a single spheroid per well of defined size and
cell number (A375 melanoma cells: 3000 cells/spheroid;
HUVEC: 750 cells/spheroid).
In Vitro Angiogenesis Assay
In vitro angiogenesis in collagen gels was quantitated
using endothelial cell spheroids as described previously
(www.spherogenex.de) [32]. In brief, spheroids containing
750 cells each were generated overnight after which they
were embedded into collagen gels. The gels were incubated
at 37jC, 5% CO2, and 100% humidity. After 24 hours, in vitro
angiogenesis was digitally quantitated by measuring the
length of the sprouts that had grown out of each spheroid
(ocular grid at  100 magnification) using the digital imag-
ing software DP-Soft (Olympus, Hamburg, Germany) ana-
lyzing at least 10 spheroids per experimental group and
experiment.
Xenograft Experiments
Female athymic nude mice (NMRI nu /nu) were pur-
chased from Elevage Janvier (Le Genest-St-Isle, France).
The mice were housed and maintained under controlled
conditions in individually ventilated cages (IVCs) (Ventirack,
Biozone, UK) and routinely used at 6 to 8 weeks of age. All
experiments were carried out according to the guidelines of
the Animal Committee of the Regierungspra¨sidium Freiburg
(Germany). The subcutaneous injection of 1  106 cells into
the dorsal flanks was performed using a 29-gauge needle
syringe. Tumor growth was quantitated by caliper measure-
ments every other day. Tumor volume (mm3) was calculated
by calipering the largest diameter (a) and its perpendicular
(b) according to the formula, 0.5ab2. Animals were sacrificed
on day 16 and tumors were weighed and processed for
morphological analysis.
Histochemical Analysis
Paraffin sections (4 mm) and cryosections (5 mm) were
cut for histochemical analyses. Deparaffinized and rehy-
drated paraffin sections and cryosections were incubated
with 3% H2O2 to inhibit endogenous peroxidase. After
washings in PBS, the sections were incubated for 30
minutes with blocking solution (10% normal rabbit serum)
followed by incubation with the corresponding primary anti-
body (anti–mouse CD34, MEC 14.7; anti–mouse CD31,
MEC 13.3) in a humid chamber at room temperature for
2 hours. They were then incubated with secondary antibody
(biotinylated rabbit anti–rat immunoglobulin antibody) and
exposed to streptavidin peroxidase, developed with diami-
nobenzidine as substrate, and weakly counterstained with
Meyer’s Hemalaun. Microvessel density was determined by
counting the number of CD34+ blood vessels within five
randomly selected areas (high-power field,  200) of two
sections of each tumor.
For double immunofluorescence analyses, 4% parafor-
maldehyde (PFA) postfixed cryosections were probed with
primary antibodies against CD31 (MEC 13.3) and EphB4,
which were then detected by incubating the sections with
fluorescence-labeled secondary antibodies [fluorescein
isothiocyanate (FITC)– labeled rabbit anti– rat immuno-
globulin; biotinylated rabbit anti –goat immunoglobulin;
DAKO] and R-Phycoerythrin (RPE)-labeled streptavidin
(DAKO).
For histochemical detection of cell proliferation in tumor
tissue, frozen sections were fixed in 4% PFA for 15 minutes,
blocked with PBS containing 1% FCS and 0.2% Tween for
30 minutes, and incubated with anti– rabbit phospho-H3
antibody in a humid chamber for 60 minutes. Phospho-H3
was preferred over PCNA or Ki67 as it is detectable in a
narrow window of the cell cycle detecting M-phase cells.
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Following washes, the secondary antibody (FITC-labeled
goat anti–rabbit IgG; Dianova, Hamburg, Germany) was
incubated for 30 minutes and counterstained with 4V,6-Dia-
midine-2V-phenylindole dihydrochloride (DAPI). Apoptosis
was assessed using an apoptosis detection kit according to
the manufacturer’s instructions (Immunotech, Marseille,
France). Slides were quantitatively analyzed by counting
the number of positive cells in 10 randomly selected micro-
scopic fields of view (high magnification,  200) of two
sections of each tumor.
Statistical Analysis
All results are expressed as mean ± SD unless indicated
otherwise. Differences between experimental groups were
analyzed by unpaired Student’s t-test. P values < .05 were
considered statistically significant.
Results
EphB4-Induced Capillary Sprout Formation Is Inhibited by
Soluble Monomeric EphB4
HUVECs express ephrinB2, and activation of reverse
endothelial ephrinB2 signaling by dimeric or clustered
EphB4-Fc stimulates sprouting angiogenesis [13]. We
employed a spheroidal three-dimensional in vitro angiogen-
esis assay [32] to study if dimeric EphB4 is also capable of
enhancing VEGF-induced proangiogenic effects. Sprouting
of HUVECs originating from collagen gel–embedded sphe-
roids can be robustly stimulated with concentrations of VEGF
as low as 2 ng/ml (Figure 1, A and B ). Dimeric EphB4-Fc
does not just stimulate capillary sprouting on its own, but also
enhances VEGF induced in gel sprouting angiogenesis
(Figure 1, A and C). In turn, monomeric soluble EphB4
consisting of the extracellular domain of EphB4 does not
affect basal or VEGF-induced sprouting angiogenesis, but
completely blocks EphB4-Fc– induced enhancement of
VEGF-induced sprouting angiogenesis (Figure 1, A and D).
Despite the lower avidity of monomeric sEphB4 compared to
dimeric EphB4-Fc (data not shown), these experiments
demonstrate the ability of excess monomeric sEphB4 to
functionally neutralize ephrinB2 signaling–mediated proan-
giogenic effects.
Growth of sEphB4-Expressing A375 Tumors Is Dramatically
Impaired
Based on the observed in vitro angioinhibitory effects of
sEphB4, we generated constitutively sEphB4-expressing
A375 melanoma cells in order to study the effect of sEphB4
on tumor growth and angiogenesis. A375 melanoma cells
were employed for these experiments in consideration of
their robust angiogenic phenotype associated, among
others, with intense VEGF, VEGF-C, and Ang-1 expression
(Ref. [30] and unpublished data). Likewise, RT-PCR screen-
ing experiments had confirmed that A375 cells do not
express EphB4 (Figure 2A). Yet, further analyses identified
A375 cells as an EphB1+, EphB2+, and ephrinB2+ cell
population (Figure 2A). Transfected A375 cells express
abundant amounts of sEphB4 as evidenced by an intense
Northern blot signal (Figure 2B) as well as the detection of
sEphB4 protein in the supernatant of transfected cells
(Figure 2C ). We had opted to employ monomeric sEphB4
in consideration of the fact that dimeric sEphB4-Fc acts
agonistically and proangiogenically on reverse EphrinB2
signaling (Figure 1) [13,33] similar to the proangiogenic
function of reverse ephrinB1 signaling [34]. Dimeric
sEphB4-Fc was found to enhance VEGF-induced angiogen-
esis in vivo in a subcutaneous chamber model, whereas
monomeric sEphB4 inhibited VEGF-induced angiogenesis in
this model (Martiny-Baron et al., unpublished observations).
Soluble EphB4-expressing and mock-transfected A375
melanoma cells were subcutaneously implanted into nude
mice. Mock-transfected A375 cells show an exponential
growth curve (Figure 2D) corresponding to the growth of
the parental cells and grow to a tumor weight of about 1 g
(Figure 2, E and F ). In contrast, sEphB4-expressing tumors
 
 
Figure 1. Effect of monomeric and dimeric soluble EphB4 on gel sprouting
angiogenesis. Concentrations as low as 2 ng/ml VEGF induce a robust
sprouting angiogenesis effect originating from collagen gel –embedded
HUVEC spheroids (negative control versus positive control) (A and B).
Dimeric EphB4-Fc (5 g/ml) significantly enhances VEGF-induced sprouting
angiogenesis (*P < .05) (A and C). In contrast, soluble monomeric EphB4
(5 g/ml) does not affect VEGF-induced sprouting angiogenesis. An excess
of monomeric sEphB4 (25 g/ml), however, completely abrogates EphB4-Fc
induced sprouting angiogenesis (*P < .05) (A and D). Scale bar, 100 m.
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grow significantly more slowly (Figure 2D), which leads to the
formation of small tumors with a tumor weight below 0.2 g
(Figure 2, E and F ).
Microvessel Density Is Moderately Reduced in sEphB4-
Expressing Tumors
Vessel density of sEphB4 and mock-transfected A375
tumors was assessed by counting CD34+ microvessels.
A375 melanomas have a prominent proangiogenic pheno-
type [30] as evidenced by a dense network of microvessels
(Figure 3, A and C ). Total microvessel density in sEphB4-
expressing tumors is moderately reduced by 19% (P < .05;
Figure 3, B and C ). Colocalization of the endothelial cell
marker, CD31, with the mural cell marker, desmin, identified
a subtle, nonsignificant difference of mural cell coverage of
tumor microvessels (36.3 ± 7.6% vs 28.4 ± 8.0%).
For a more detailed analysis of the phenotype of sEphB4-
expressing tumors, we developed an EphB4/CD31 double-
staining technique, which revealed marked variations in the
intensity of sEphB4 expression in different areas of the
tumor. Areas with the highest sEphB4 levels were found to
correspond to low microvessel densities (Figure 3, D and E ).
Likewise, microvessels in areas with the highest sEphB4
expression had a disturbed morphology when compared to
tumor areas with low sEphB4 expression or mock-trans-
fected tumors. Altered vascular morphology was character-
ized by very small immunoreactive CD31 spots indicative of
collapsed vessels without lumen (Figure 3E ).
Soluble EphB4-Expressing A375 Melanoma Cells Cannot
Form Proper Adhesive Contacts and Have Reduced Rates
of Proliferation and Apoptosis In Vitro and In Vivo
Soluble EphB4 significantly inhibited tumor angiogenesis
(Figure 3). Yet, the moderate inhibition of angiogenesis was
not likely to be solely responsible for the dramatic tumor-
inhibitory effect of sEphB4 (Figure 2). We therefore hypoth-
esized that the dramatic tumor-inhibitory effect of sEphB4
expression in A375 melanomas may have been the conse-
quence of a combined antiangiogenic and antitumorigenic
effect of sEphB4, and have decided to characterize the
properties of sEphB4-expressing A375 cells in more detail.
Short-term thymidine incorporation experiments did not re-
veal a difference in the proliferation of sEphB4-transfected
cells and mock-transfected cells grown in monolayer culture
(data not shown). Likewise, direct counting of proliferating
cells showed identical proliferation kinetics for the first
4 days, after which the two cell populations started to diverge
(Figure 4A). Yet, this difference turned out to be nonsig-
nificant when comparing growth rates (comparison of
log-transformed proliferation data). Both sEphB4 and mock-
transfected cells were similarly capable of anchorage-inde-
pendent growth as evidenced by their ability to form colonies
in soft agar with comparable growth properties within the first
few days. However, sEphB4-transfected A375 cells formed
smaller colonies after 14 days in culture (Figure 4, B and C ).
We therefore analyzed the cell cycle distribution of mock and
sEphB4-transfected A375 cells grown for 13 days in soft
agar. Soluble EphB4-transfected cells had significantly
  
Figure 2. Growth of sEphB4-expressing and mock-transfected A375 mela-
nomas. Wild-type A375 cells express the receptors EphB1 and EphB2 as well
as the EphB2/B3/B4 ligand, ephrinB2. Expression of the receptors EphB3 and
EphB4 is not detectable by RT-PCR analysis (A). Constitutively sEphB4-
transfected cells abundantly express sEphB4 mRNA (B) (Northern blot) and
sEphB4 protein (C) (Western blot analysis of supernatant; SVEC4-10 cells
expressing endogenous full-length EphB4 used as control). Subcutaneous
injection of A375 cells (106 each) into nude mice leads to rapid tumor growth
(D and F). Mock-transfected tumors form reddish tumors indicative of intense
vascularization (E). In contrast, sEphB4-expressing A375 melanomas form
small subcutaneous nodules (E) with strongly reduced total tumor weight
(F) (**P <0.001). The figure shows the mean ± SEM of one of three
experiments with similar results analyzing at least 12 mice per data point.
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reduced numbers of sub-G1 cells (14.5% vs 3.5%, P < .01)
indicating an altered turnover of the cells (Figure 4,D and E ).
The most dramatic phenotypic difference between sEphB4
and mock-transfected cells was observed when assessing
their intercellular adhesiveness in three-dimensional spher-
oid assays. Mock-transfected cells formed compacted round
spheroidal aggregates. In turn, sEphB4-transfected cells
could not form spheroids, but rather organized into a sheet
of loosely adherent cells (Figure 4, F and G).
The observed cell–cell interaction differences (adhesion,
spheroidal organization, and size and cell cycle distribution
of soft agar colonies) prompted us to further study prolifer-
ation and apoptosis in the wild-type and sEphB4-expressing
tumors. Staining of the tumor sections for Ki67 identified that
the vast majority of the cells were uniformly Ki67+. We
therefore employed an anti–phospo-H3 antibody, which
identifies M-phase cells and can therefore be used as a
proliferation marker that identifies a narrower window of the
cell cycle. Phospho-H3 staining detected significantly lower
numbers of mitotic tumor cells in the sEphB4-expressing
tumors compared to the mock-transfected tumors
(Figure 4H ). Surprisingly and corresponding to the soft
agar cell cycle distribution experiments, sEphB4-expressing
tumors also had significantly reduced levels of apoptosis as
detected by transferase-mediated dUTP nick end labeling
(TUNEL) staining (Figure 4 I ). Collectively, the detailed anal-
ysis of sEphB4-transfected A375 cells in vitro and in vivo
showed that tumorigenicity (soft agar assay) and cell prolif-
eration in planar cell culture systems as such are not affected
by sEphB4. Yet, sEphB4 acts to interfere with tumor cell–cell
communication as evidenced by a perturbed cell adhesion
phenotype and, concomitantly, reduced cell proliferation and
apoptosis.
Expression of EphB4 Is Enhanced in Colon Cancer
The above analysis of sEphB4-expressing A375 tumors
suggested that EphB/ephrinB signaling controls multiple
endothelial cell and tumor cell interactions related to tumor
progression and that sEphB4 interferes with tumor growth
and angiogenesis in EphB/ephrinB2–expressing tumors.
EphB4 and ephrinB2 have recently been shown to be
expressed by epithelial cells in the intestines, where they
control the spatial organization of differentiating epithelial
cells toward each other [14]. We therefore analyzed the
expression of EphB4 and ephrinB2 in human colon tumors.
RNA was isolated from 15 matched pairs of colon tumor
tissues and adjacent tumor cell– free tissue biopsies and was
analyzed by Northern blot. EphrinB2 was found to be
expressed at the same level in tumor and adjacent tissues
(Figure 5, A and B ). In contrast, EphB4 expression was
found to be two-fold upregulated in colon carcinoma tissues
(P < .001) (Figure 5, A and B).
Discussion
A number of different avenues have been developed to
therapeutically interfere with tumor angiogenic signaling
mechanisms including antibodies to angiogenic cytokines
[35] and their receptors [36], dominant-negative receptors
[37], and soluble receptors, which have been used widely as
cytokine traps to therapeutically interfere with tumor-associ-
ated angiogenesis [30,38–40].
Figure 3. Vascularization of mock-transfected (A) and sEphB4-expressing (B) A375 melanomas. Tumor sections were stained for the endothelial cell marker,
CD34, and the microvessel density was quantitated in at least five high-power fields per tumor section. Total microvessel density is reduced by approximately 20%
in sEphB4-expressing tumors (**P < 0.01) (C). The figure shows the mean±SEM of one of three experiments with similar results, analyzing at least 14 tumor
sections per experimental group. Double staining for the endothelial cell marker, CD31 (green fluorescence), and for sEphB4 expression (red fluorescence)
identified a heterogeneous intratumoral sEphB4 expression pattern with areas of the highest expression (dotted line) being adjacent to areas of lower expression.
Regions of high sEphB4 expression correspond to the regions with the lowest microvessel density (D, upper left area). Likewise, microvessels in low sEphB4 areas
can regularly be identified as elongated lumenized structures, whereas microvessels in high sEphB4-expressing areas are characterized by small CD31+ dots
indicative of collapsed vessels (E, dotted lines).
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EphB receptors and their corresponding ephrinB ligands
have been shown to be critically involved in vascular mor-
phogenesis [9]. Yet, they have not been explored much as
therapeutic target to interfere with tumor growth and angio-
genesis. EphB receptor–expressing cells engage bidirec-
tional signal transduction mechanisms on interaction with
corresponding ephrinB ligand–expressing cells. As such,
dimeric (or clustered) soluble EphB receptors competitively
inhibit EphB receptors. Yet, they may also act as agonists of
reverse signaling in ephrinB ligand–expressing cells. Re-
verse signaling ephrinB2 activation by dimeric (or clustered)
soluble EphB4 elicits a proangiogenic effect [13], contribut-
ing to the arteriolizing effect of ephrinB2 [9]. We have
consequently studied the effect of soluble monomeric EphB4
(sEphB4) on tumor growth and angiogenesis. The experi-
ments show that: 1) sEphB4 inhibits gel sprouting angiogen-
esis induced by dimeric EphB4-Fc; 2) sEphB4 dramatically
inhibits growth of sEphB4-expressing A375 melanomas; 3)
sEphB4 interferes with tumor angiogenesis and vessel or-
ganization; 4) sEphB4 does not affect primary tumorigenicity
parameters of A375 cells, but interferes with tumor cell–cell
adhesion and affects cell proliferation and apoptosis in three-
dimensional systems in vitro and in vivo; and 5) EphB4 is
upregulated in human colon cancers.
The experiments suggest that the EphB/ephrinB system
may offer an attractive molecular system as a therapeutic
target. Originally believed to exclusively act by providing
positional guidance cues during neuronal patterning, the
rate-limiting role of EphB receptors and ephrinB ligands in
vascular patterning is now well established [9]. Furthermore,
EphB receptors and ephrinB ligands have been shown to
control spatial organization of intestinal epithelial cells [14].
Corresponding to these findings, we observed significantly
upregulated levels of EphB4 expression in colon cancers,
confirming and extending the findings by Liu et al. [16] and
Stephenson et al. [23]. We did not observe an overexpres-
sion of ephrinB2 in colon cancers, which is prominently
expressed by angiogenic endothelial cells [10,11]. This lack
of detectable ephrinB2 overexpression in our Northern blot
screening experiments of colon carcinomas is most likely
 
Figure 4. Analysis of mock-transfected wild-type and sEphB4-expressing A375 melanoma cells in culture and tumors. Expression of sEphB4 has only a minor
effect on proliferation of A375 as evidenced by a nonsignificant difference in the tumor cells’ growth rate (A) (n = 3 in duplicates). Likewise, both sEphB4-transfected
and mock-transfected cells similarly form colonies in a 14-day soft agar assay (B and C). Yet, colonies of sEphB4-expressing cells remain smaller (B versus C) and
the cells have an altered cell cycle distribution pattern with significantly reduced levels of sub-G1 cells (n = 3; P < .05) (D and E). Mock-transfected A375 cells form
compact three-dimensional spheroids (F). In contrast, sEphB4-expressing A375 cells do not form compacted three-dimensional spheroids (G). Soluble EphB4-
expressing A375 tumors contain significantly less mitotic cells as evidenced by staining with an anti –phospho-H3 antibody (H) and fewer TUNEL+ cells (I) (n = 4;
*P < .05).
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reflective of the strong dilution of the endothelial cell–derived
Northern blot signal by the vast majority of ephrinB2-expre-
ssing tumor cells. In turn, it also highlights the necessity for a
strong purification of the endothelial cell compartment in any
kind of angiogenesis-related genomic screening effort [41].
The dramatic therapeutic effect of sEphB4 on the growth
of A375 melanomas is the result of interfering with multiple
EphB/ephrinB2 interactions that govern both tumor cell and
angiogenic endothelial cell properties at later stages of
tumor progression. Soluble EphB4 reduces intratumoral
microvessel density by approximately 20%. This may not
be sufficient to account for the observed potent antitumori-
genic effect. Instead, direct antitumorigenic effects are also
elicited as a consequence of sEphB4 expression. This was
surprising as A375 cells do not express EphB4. Yet, they do
express EphB2, which is also a receptor for ephrinB2. Con-
sequently, the blocking of ephrinB2 by sEphB4 also interferes
with EphB2/ephrinB2 interactions. Soluble EphB4 does not
directly affect tumor cell proliferation. Instead, it affects the
tumor cells’ ability to form proper cell–cell contacts, resulting
in the formation of small colonies in soft agar experiments
even though soft agar colony formation as such is not
affected by sEphB4. Rates of cell proliferation and apoptosis
are both reduced in vivo. It appears likely that the dominance
of reduced proliferation over the reduced rate of apoptosis is
likely to account for the observed reduction in tumor growth.
Taken together, the data strongly suggest that the dramat-
ic tumor growth– inhibitory effect in the sEphB4-expressing
tumors has resulted from a combined antiangiogenic and
antitumorigenic effect. Likewise, multicompartment expres-
sion of EphB receptors and ephrinB ligands by endothelial
cells and tumor cells may also suggest that EphB/ephrinB
signalingmaynot just control interactionsbetween tumor cells
and between endothelial cells, but also drive tumor endothe-
lial cell interactions. As such, it will be interesting to study if
Eph/ephrin interactions are capable of controlling tumor cell
dissemination mechanisms as they relate to metastasis.
The present study has shown that sEphB4 exerts dual
effects by affecting both the tumor and the vascular com-
partment. It is tempting to speculate on the multiple cellular
interactions that are governed by bidirectional EphB/ephrinB
signaling during tumor progression and metastasis. What
was originally identified as a presumably neuronal-specifi-
cally acting molecular system [6] is now emerging as
a universal cell–cell interaction and communication regulat-
ing system that transduces positional information to the cells
of the vascular system [7–9], the intestinal system [14],
different tumor types [15–17], and likely other hitherto not
yet identified cells and organs. Given the multicompartment
and multicellular character of the EphB/ephrinB system, it is
likely that additional EphB/ephrinB–regulated cell–cell inter-
actions will be uncovered in the near future. It also suggests
that the EphB/ephrinB system may emerge as an attractive
therapeutic target for a number of pathological conditions.
Monomeric sEphB4 interferes potently with growth and
angiogenesis of A375 melanomas. Yet, these findings need
to be interpreted as proof-of-principle experiments aimed at
exploring the EphB/ephrinB axis as a potential antitumori-
genic therapeutic target. Monomeric receptors are notori-
ously known as poor inhibitors due to their low affinity and
avidity compared to dimeric or clustered receptors [38]. This
was reflected in the present study by the requirement to
employ excess amounts of monomeric sEphB4 to inhibit
dimeric EphB4-Fc induced in gel sprouting angiogenesis
(Figure 1). We observed that the antivascular effect of
sEphB4 was most pronounced in intratumoral areas with
highest sEphB4 expression (Figure 3). Recent experiments
have proposed a scheme to design multidomain high-affinity
receptor bodies as antagonizing cytokine traps, which will
also allow an attractive avenue toward the development of
reagents that can therapeutically interfere with Eph/ephrin
signaling [38].
Taken together, the present study has shown that EphB/
ephrinB interactions are critically involved in tumor progres-
sion and angiogenesis and offer an attractive therapeutic
Figure 5. Expression of EphB4 and ephrinB2 mRNA in matched pairs of
colon carcinomas and adjacent normal tissue. (A) Total RNA isolated from
biopsies of tumor (T) and adjacent (A) tissues from 15 patients was isolated
and analyzed by Northern blot analysis (upper panel; lower panel: 28S and
18S loading controls). (B) Ratio of tumor versus adjacent normal tissue (T/A)
expression levels of EphB4 and ephrinB2 quantitated by comparative
densitometric analysis of Northern blot signals (normalized to loading
controls). Relative ephrinB2 expression levels do not differ in colon tumors
and adjacent normal tissue. In contrast, EphB4 expression is two-fold
upregulated in human colon cancers (**P < .001).
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target that is also supported by the growing list of human
tumors that overexpress EphB receptors or ephrinB ligands,
including colon cancers (this study and Refs. [16,23]), mel-
anomas [24], endometrial tumors [25], neuroblastomas
[27,28], and gastric tumors [42]. The experiments offer an
attractive rationale for the development of specific high-
affinity biological and small-molecular-weight pharmacolog-
ical inhibitors of Eph/ephrin signaling. They also highlight the
complexity of Eph/ephrin–driven cellular interactions con-
trolling the tumor cell as well as the vascular compartment.
Future work aimed at studying the complexity of the multi-
compartment Eph/ephrin signaling network may well shed
further light into the complexity of tumor cell–endothelial cell
interactions and contribute to a better understanding of
tumor progression mechanisms as they relate to metastatic
dissemination of tumor cells.
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